All In MedTech

FDA Clearance Tracker · P030004-S035

Onyx Liquid Embolic System (LES)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 8, 2025

Approved

Time to decision

419 days

Received Oct 15, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P030004-S035
Device name
Onyx Liquid Embolic System (LES)
Applicant location
Irvine, CA
Received
Oct 15, 2024
Decided
Dec 8, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P030004

Device type

Device class
Class III

Every decision under product code SGU

FDA's approval statement

As written in FDA's record.

Onyx Liquid Embolic System (LES) is indicated for embolization of the middle meningeal artery (MMA) as an adjunct to surgery for the treatment of symptomatic subacute or chronic subdural hematoma (SDH).

Source documents

Other decisions for Ev3 Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.